India parliament passes bill backing regional biotech institute


India's lower house of parliament passed a bill this week to back a regional biotech center aimed at promoting expertise and research in South Asia and wider in the Asian region, the Business Standard newspaper reports.

The Regional Centre for Biotechnology--to be located in the northern state of Haryana--would offer degrees up to the doctorate level, while also serving as a home to academics with access to research facilities in biotechnology, the newspaper said. Funding and other details were not available.

India has lagged in comparison to other Asian nations such as Japan, China and Australia in growing a local biotech industry--although established drug companies such as Dr. Reddy's Laboratories are making a push into biosimilar and licensed drugs, while smaller firms in the space are also on the research scene.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In November of last year, the government said it wanted to add 1,500 startups in the next 2 to 3 years in biotechnology--up from around 500 at the end of 2015. Currently, India's biotech industry is around 2% of the global biotech sector and ranked 12th in the world and third in the Asia-Pacific region, according to a recent report.

The new center would seek to aid growth domestically in biotech as well as establish links abroad by offering course work training and research in biotechnology to students and researchers.

- here's the story from Business Standard


Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.